Interstitial Cystitis, ChronicHistologyICNCT03069053
Clinical Features and Histologic Findings in Bladder Pain Syndrome/Interstitial Cystitis
An observational study of Interstitial Cystitis, Chronic and Painful Bladder Syndrome, run by Fondazione IRCCS Policlinico San Matteo di Pavia at 4 sites in Italy.
Trial summary
Objectives- to find out whether a correlation exists between denudation of urothelium and diagnosic delay in patients with BPS / IC, secondary aim was to search a correlation between impact of symptoms evaluated with ICSI-ICPI and number of comorbid conditions associated with BPS-IC. Read more about this study
- Who is it for?
- Ages 19 to 67 years
- Conditions the study is for
- Interstitial Cystitis, Chronic, Painful Bladder Syndrome
- How many people
- 57 participants
- Where
- 4 sitesItaly
- Study dates
- 1 Jul 2016to 20 Feb 2017
- How long will I take part?
- 14 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 67 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Fifty-seven consecutive patients underwent cystoscopy under anaesthesia to classify those cases suspected of BPS/IC
Who may be able to join
- Patients reported long-lasting irritative bladder symptoms, including urgency, daytime frequency of seven or more episodes, nocturia, and pain in the lower abdomen, lower back, vagina or perineum during filling or after micturition.
Who cannot join
- Alternative diagnoses such as urinary tract infection (UTI) were excluded. Confusable diseases were ruled out by thorough history, clinical examination, urine analysis and imaging.
Trial locations and contacts
4 sites in 1 country.
Italy4 sites
Clinical Epidemiology and Biometric Unit, Fondazione IRCCS Policlinico San Matteo
Pavia, 27100
Histology and Pathology Service, Fondazione IRCCS Policlinico San Matteo
Pavia, 27100
Obstetric and Gynecological Clinic, Fondazione IRCCS Policlinico San Matteo
Pavia, 27100
Urology Department Fondazione IRCCS Policlinico San Matteo
Pavia, 27100
About this study
Official title: Clinical Features and Histologic Findings in Bladder Pain Syndrome/Interstitial Cystitis (BPS/IS): New Findings on Useful Correlations
Objectives- to find out whether a correlation exists between denudation of urothelium and diagnosic delay in patients with BPS / IC, secondary aim was to search a correlation between impact of symptoms evaluated with ICSI-ICPI and number of comorbid conditions associated with BPS-IC.
Patients and Methods- Fifty-seven consecutive patients underwent cystoscopy under anaesthesia to classify those cases suspected of BPS/IC. As for the evaluation of the ICSI-ICPI scores we considered significant relevant values those ≥ 12. Patients underwent cystoscopy with hydrodistension under general (90%) or locoregional anaesthesia. Bladder biopsies were taken, including detrusor muscle, from those areas with the most apparent bladder wall lesions. All biopsies were then fixed in 4% formalin and sent to the Pathologist for examination.
Read the detailed description
Between 2005 and 2016, in our Department 57 consecutive patients underwent cystoscopy under anaesthesia to classify those cases suspected of BPS/IC. Patients reported long-lasting irritative bladder symptoms, including urgency, daytime frequency of seven or more episodes, nocturia, and pain in the lower abdomen, lower back, vagina or perineum during filling or after micturition. Alternative diagnoses such as urinary tract infection (UTI) were excluded. Confusable diseases were ruled out by thorough history, clinical examination, urine analysis and imaging.
By means of a detailed medical history we considered the time of symptom onset, frequency of micturitions, the presence of associated diseases. All patients were given the same questionnaire (O'Leary-Sant Interstitial Cystitis Symptom and Problem Index) (19), filled at the time of bladder biopsy.
As for the evaluation of the ICSI-ICPI scores we considered significant relevant values those ≥ 12.
All patients underwent cystoscopy with hydrodistension under general (90%) or locoregional anaesthesia. A rigid cystoscope with a Ch. 22 caliber was used, mannitol solution was used as filling fluid, and infusion height was 80 cm above the symphysis pubis. During filling the bladder was continuously inspected. At maximal capacity, distension was maintained until spontaneous filling stopped and maximum capacity was reached. At this point the bladder was drained and bladder walls and mucosa were closely examined . The bladder was then filled again at approximately half capacity, and at least three deep biopsies were taken, including detrusor muscle, from those areas with the most apparent bladder wall lesions.
All biopsies were then fixed in 4% formalin and sent to the Pathologist for examination. It was specifically asked to assess the presence of urothelial denudation, inflammatory infiltrate, counts of mast cells in the submucosa and detrusor, presence of intrafascicular fibrosis and submucosal bleeding. A cut-off of 28 mast cells / mm2 was used for the assessment of detrusor mastocytosis.
Morphologic Study Biopsy samples were cut in 5-μm-thick sections, then stained with the following reagents for morphologic evaluation: Hematoxylin-Eosin, Giemsa and Masson Tricromic Stain. This procedure was performed by automatic stainers (Leica, mod. ST5020 and mod. Autostainer™ XL).
In each biopsy the following parameters were evaluated, according to the recommendations reported by Hanno et al. (20) and reported in Table 1.
If the biopsy wasn't adequately sized (< 1 mm2-wide), we decided to evaluate the most reliable parameters, giving a N.V. (Not Valuable) response to the others.
Such parameters were single-blindly studied by two independent pathologists using optic microscopes (Nikon, mod. Eclipse™ E400 and mod. Eclipse™ CI) and discordant cases were then discussed jointly.
Immunohistochemical Studies Immunohistochemical reactions with Dako monoclonal antibody anti-Human Mast-cell Tryptase (Clone AA1; IgG1, Kappa), at 1:4000 dilution, were performed in order to highlight the mast-cell component of the inflammatory infiltrate, and then to quantify it. According to the protocol followed at the Laboratory of Immunohistochemistry of the Pathology Unit the automatic immunostainer Dako Omnis™ was used.
Evaluation of the Immunostainings
The reactions were evaluated using optic microscopes (Nikon, mod. Eclipse™ E400 and mod. Eclipse™ CI). The following parameters were studied:
- Number of mast-cells/mm2 of mucosa;
- Number of mast-cells/mm2 of submucosa;
- Number of mast-cells/mm2 of the detrusor layer. In order to obtain the highest accuracy, a single-blind evaluation was performed by two independent pathologists; discordant or uncertain cases were then discussed jointly.
All patients were evaluated retrospectively using patient files, they were given a score between 0 to 5 according to the presence of the following criteria (each criteria counting one point): pain, nocturia, a bladder capacity of 500 mL, glomerulations, or interfascicular fibrosis.
- Medical subject headings
- Cystitis, Interstitial
What is being measured
The primary outcome is the main question the study is designed to answer.
correlation between denudation of urothelium and diagnosic delay
to find out whether a correlation exists between denudation of urothelium and diagnosic delay in patients with BPS / IC
Measured: 11 years
Secondary outcomes (1)
correlation between impact of symptoms evaluated with ICSI-ICPI and number of comorbid conditions associated with IC
to search a correlation between impact of symptoms evaluated with ICSI-ICPI and number of comorbid conditions associated with IC
Measured: 11 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2017
- Study start1 Jul 2016
- Primary completion15 Dec 2016
- Study completion20 Feb 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Interstitial Cystitis, ChronicStudies of the same condition, open and under way.
- More trials run by Fondazione IRCCS Policlinico San Matteo di PaviaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 57 participants (actual)
- Target duration
- 14 Years
Sponsor and investigators
- Lead sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Daniele Porru, Fondazione IRCCS Policlinico San Matteo di Pavia
- Investigators
- DANIELE PORRU, MD, Principal investigator, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03069053
- Sponsor's protocol ID
- IRCCSPSMATTEO
- Acronym
- HistologyIC
- Status last verified
- Feb 2017
- First submitted
- 22 Feb 2017
- Last updated
- 3 Mar 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Mar 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Features and Histologic Findings in Bladder Pain Syndrome/Interstitial Cystitis (BPS/IS): New Findings on Useful Correlations
- ClinicalTrials.gov ID
- NCT03069053
- Acronym / sponsor ID
- HistologyIC / IRCCSPSMATTEO
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 57 participants (actual)
- Lead sponsor
- Fondazione IRCCS Policlinico San Matteo di PaviaUniversity, hospital or other
- Study start
- 1 Jul 2016 (actual)
- Primary completion
- 15 Dec 2016 (actual)
- Study completion
- 20 Feb 2017 (actual)
- First posted
- 3 Mar 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objectives- to find out whether a correlation exists between denudation of urothelium and diagnosic delay in patients with BPS / IC, secondary aim was to search a correlation between impact of symptoms evaluated with ICSI-ICPI and number of comorbid conditions associated with BPS-IC.
Patients and Methods- Fifty-seven consecutive patients underwent cystoscopy under anaesthesia to classify those cases suspected of BPS/IC. As for the evaluation of the ICSI-ICPI scores we considered significant relevant values those ≥ 12. Patients underwent cystoscopy with hydrodistension under general (90%) or locoregional anaesthesia. Bladder biopsies were taken, including detrusor muscle, from those areas with the most apparent bladder wall lesions. All biopsies were then fixed in 4% formalin and sent to the Pathologist for examination.
Detailed description
Between 2005 and 2016, in our Department 57 consecutive patients underwent cystoscopy under anaesthesia to classify those cases suspected of BPS/IC. Patients reported long-lasting irritative bladder symptoms, including urgency, daytime frequency of seven or more episodes, nocturia, and pain in the lower abdomen, lower back, vagina or perineum during filling or after micturition. Alternative diagnoses such as urinary tract infection (UTI) were excluded. Confusable diseases were ruled out by thorough history, clinical examination, urine analysis and imaging.
By means of a detailed medical history we considered the time of symptom onset, frequency of micturitions, the presence of associated diseases. All patients were given the same questionnaire (O'Leary-Sant Interstitial Cystitis Symptom and Problem Index) (19), filled at the time of bladder biopsy.
As for the evaluation of the ICSI-ICPI scores we considered significant relevant values those ≥ 12.
All patients underwent cystoscopy with hydrodistension under general (90%) or locoregional anaesthesia. A rigid cystoscope with a Ch. 22 caliber was used, mannitol solution was used as filling fluid, and infusion height was 80 cm above the symphysis pubis. During filling the bladder was continuously inspected. At maximal capacity, distension was maintained until spontaneous filling stopped and maximum capacity was reached. At this point the bladder was drained and bladder walls and mucosa were closely examined . The bladder was then filled again at approximately half capacity, and at least three deep biopsies were taken, including detrusor muscle, from those areas with the most apparent bladder wall lesions.
All biopsies were then fixed in 4% formalin and sent to the Pathologist for examination. It was specifically asked to assess the presence of urothelial denudation, inflammatory infiltrate, counts of mast cells in the submucosa and detrusor, presence of intrafascicular fibrosis and submucosal bleeding. A cut-off of 28 mast cells / mm2 was used for the assessment of detrusor mastocytosis.
Morphologic Study Biopsy samples were cut in 5-μm-thick sections, then stained with the following reagents for morphologic evaluation: Hematoxylin-Eosin, Giemsa and Masson Tricromic Stain. This procedure was performed by automatic stainers (Leica, mod. ST5020 and mod. Autostainer™ XL).
In each biopsy the following parameters were evaluated, according to the recommendations reported by Hanno et al. (20) and reported in Table 1.
If the biopsy wasn't adequately sized (< 1 mm2-wide), we decided to evaluate the most reliable parameters, giving a N.V. (Not Valuable) response to the others.
Such parameters were single-blindly studied by two independent pathologists using optic microscopes (Nikon, mod. Eclipse™ E400 and mod. Eclipse™ CI) and discordant cases were then discussed jointly.
Immunohistochemical Studies Immunohistochemical reactions with Dako monoclonal antibody anti-Human Mast-cell Tryptase (Clone AA1; IgG1, Kappa), at 1:4000 dilution, were performed in order to highlight the mast-cell component of the inflammatory infiltrate, and then to quantify it. According to the protocol followed at the Laboratory of Immunohistochemistry of the Pathology Unit the automatic immunostainer Dako Omnis™ was used.
Evaluation of the Immunostainings
The reactions were evaluated using optic microscopes (Nikon, mod. Eclipse™ E400 and mod. Eclipse™ CI). The following parameters were studied:
- Number of mast-cells/mm2 of mucosa;
- Number of mast-cells/mm2 of submucosa;
- Number of mast-cells/mm2 of the detrusor layer. In order to obtain the highest accuracy, a single-blind evaluation was performed by two independent pathologists; discordant or uncertain cases were then discussed jointly.
All patients were evaluated retrospectively using patient files, they were given a score between 0 to 5 according to the presence of the following criteria (each criteria counting one point): pain, nocturia, a bladder capacity of 500 mL, glomerulations, or interfascicular fibrosis.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 14 Years
Who may qualify
- Ages
- 19 to 67 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Fifty-seven consecutive patients underwent cystoscopy under anaesthesia to classify those cases suspected of BPS/IC
Key inclusion criteria (1 listed)
- Patients reported long-lasting irritative bladder symptoms, including urgency, daytime frequency of seven or more episodes, nocturia, and pain in the lower abdomen, lower back, vagina or perineum during filling or after micturition.
Key exclusion criteria (1 listed)
- Alternative diagnoses such as urinary tract infection (UTI) were excluded. Confusable diseases were ruled out by thorough history, clinical examination, urine analysis and imaging.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
correlation between denudation of urothelium and diagnosic delay
Time frame: 11 years
to find out whether a correlation exists between denudation of urothelium and diagnosic delay in patients with BPS / IC
1 secondary outcome
correlation between impact of symptoms evaluated with ICSI-ICPI and number of comorbid conditions associated with IC
Time frame: 11 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Mar 2017.
- Individual participant dataSharing planned: No
Related trials for Interstitial Cystitis, Chronic
Active, not recruiting
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
Bladder Cancer, Prostate Cancer
Enrolling by invitationObservational study
Migraine Medication Effects on Urinary Symptoms
Overactive Bladder, Bladder Pain Syndrome
Recruiting
EPPIC: Easing Pelvic Pain Interventions Clinical Research Program
Urologic Chronic Pelvic Pain Syndrome (UCPPS), Interstitial Cystitis
Recruiting
Investigation of PEMF Therapy for Female Patients With IC/BPS
Interstitial Cystitis, Chronic Interstitial Cystitis
Recruiting
Aerobic Exercise and Connective Tissue Massage in Painful Bladder Syndrome
Bladder Pain Syndrome, Painful Bladder Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
DANIELE PORRU, MD principal investigator
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Interstitial Cystitis, Chronic and Painful Bladder Syndrome, run by Fondazione IRCCS Policlinico San Matteo di Pavia at 4 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
correlation between denudation of urothelium and diagnosic delay (time frame: 11 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2017.